- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.10. | Novo Nordisk pens $2.1B deal for Omeros' stalled PNH drug | ||
| 14.10. | Lila Sciences adds Nvidia-backed $115M to series A, bringing total haul to $350M | ||
| 14.10. | BioCryst inks $700M Astria buyout to challenge Takeda for rare disease market | ||
| 14.10. | Kailera taps Bain-led syndicate for $600M to carry Zepbound challenger into phase 3 | ||
| 14.10. | Denali's Hunter syndrome drug latest to be hit by FDA decision delay | ||
| 13.10. | 'Not here to refine the status quo': Excellergy emerges with $70M, plans to redefine allergy therapeutics | ||
| 13.10. | Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates | ||
| 13.10. | Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohort | ||
| 13.10. | Moderna posts melanoma data behind decision to say 'I do' to IDO | ||
| 10.10. | Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure' | ||
| 10.10. | J&J in talks to buy immunology partner Protagonist: WSJ | ||
| 10.10. | Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial | ||
| 10.10. | Amid the dip, biotech execs share silver linings in a tumultuous environment | ||
| 10.10. | AstraZeneca: Building a transparent pipeline from the ground up | ||
| 10.10. | BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence | ||
| 10.10. | Shuttle Pharma launches into AI drug discovery space via $10M acquisition | ||
| 10.10. | Inflammation biotech Evommune eyes IPO to fund further dermatitis trials | ||
| 09.10. | 2 ex-Moderna leaders unveil $325M inaugural VC fund for platform biotechs | ||
| 09.10. | Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test | ||
| 09.10. | Expedition resupplies for phase 2 COPD voyage with $165M series A | ||
| 09.10. | AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413M | ||
| 09.10. | Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect | ||
| 09.10. | CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug | ||
| 08.10. | US government pumps money toward in vivo cell therapy programs | ||
| 08.10. | TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .